What is StemCyte?
StemCyte operates as a leading cord blood bank, providing essential services for the storage of newborn stem cells. Trusted by OBGYN and transplant physicians, the company offers both private and public banking options, empowering families to preserve their child's cord blood for potential life-saving medical treatments. StemCyte is distinguished by its extensive and ethnically diverse inventory, actively participating in numerous clinical trials and achieving notable transplant records. Its core mission is to offer parents peace of mind regarding their children's future health and the possibility of therapeutic interventions for a range of diseases.
How much funding has StemCyte raised?
StemCyte has raised a total of $2M across 2 funding rounds:
Debt
$1M
Debt
$963K
Debt (2020): $1M with participation from PPP
Debt (2021): $963K led by PPP
What's next for StemCyte?
The recent major strategic investment into StemCyte indicates a strong confidence in the company's business model and its future potential within the rapidly evolving biotech and healthcare sectors. This capital infusion is likely to fuel further expansion of its storage capacity, enhance its research and development initiatives, and potentially broaden its clinical trial participation. StemCyte's focus on diverse stem cell inventories and its established track record in transplants position it for continued leadership in the field of regenerative medicine, aiming to leverage this new backing for accelerated growth and innovation.
See full StemCyte company page
